期刊文献+

喀什地区维族妇女乳腺癌转移复发风险初步探讨

Kashgar Uighurs risk of metastasis and recurrence of breast cancer in womendiscussed
下载PDF
导出
摘要 目的:探讨新疆喀什地区维吾尔族妇女乳腺癌复发转移风险,为临床术后的综合治疗方案和预后评估提供可靠的依据。方法:收集本院2009~2010年行手术切除的维吾尔族妇女乳腺癌患者72例,采用免疫组化En-Vision法检测乳腺癌组织中ER、PR、HER2、CK5/6、Ki-67、E-cad,做出6项复发转移风险评估的基因表达谱分类。结果:72例患者中40岁以上年龄患者56例,占77.78%;浸润性导管癌64例,占88.89%,Ⅱ~Ⅲ级以上高级别者占78%;肿瘤大小:T2以上者61例,占85%;查到脉管浸润65例,占90.3%;有淋巴结转移者52例,占72%;激素受体阳性49例,占76.6%,HER2阳性3+患者13例,占20.3%(13/64)。结论:喀什地区维族妇女乳腺癌有较高的复发风险,激素受体阳性占77.6%,提示本地维族妇女乳腺癌大部分适用于内分泌治疗。 Objective:kashi region of xinjiang Uighur women for the transfer of risk,breast cancer recurrence of clinical postoperative comprehensive treatment scheme and provide reliable basis for prognostic evaluation. Methods:to collect our 2010 in 2009 from line of uighurs women surgical excision 72 patients with breast cancer patients.By using immunohistochemistry EnVision method(EnVision kit) detection breast cancer tissues,ER、PR、HER2、CK5/6、Ki-67,E-cad,make six relapse and metastasis risk assessment the gene expression profiles of classification. Results:72 patients with forty years age 56 cases 77.78%,accounted for;infiltrating ductal carcinoma,accounted for 64 cases 88.89%;Ⅱ-Ⅲ class above the high level,accounts for about 78%;tumor size T2 61 cases is occupied 85% above;to check,65 patients with vascular invasion of text.The electors have lymph node metastasis 52 cases,72 per cent.6 hormone receptor-positive 76.6% 49 cases of patients,HER2 positive 3+13 cases accounted for 20.3%(13/64). Conclusion:region have higher Uighur women breast cancer risk of a recurrence;Hormone receptor-positive 77.6%,hints of local Uighur women most suitable for endocrine therapy of breast cancer.
出处 《农垦医学》 2011年第1期19-21,共3页 Journal of Nongken Medicine
关键词 喀什 维吾尔族妇女 乳腺癌 免疫组化 复发转移风险 kashi Uighur women Breast cancer Immunohistochemical Relapse and metastasis risk
  • 相关文献

参考文献10

二级参考文献103

  • 1江泽飞,宋三泰,孙燕.乳腺癌内分泌治疗的基本原则和新动向——2006年美国NCCN乳癌内分泌治疗指南解读[J].临床药物治疗杂志,2006,4(2):21-25. 被引量:20
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3于慧,胡夕春.侵袭性细胞基底样乳腺癌的生物学特征[J].中华肿瘤防治杂志,2007,14(3):234-236. 被引量:4
  • 4步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 5Wolff AC, Hammond ME ,Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25 (1) :118-145.
  • 6College of American Pathologists/American Society of Clinical Oneology. HER? and you[ S/OL]. Guideline provided by CAP/ ASCO. 2007 ( 2007-01-11 ) [ 2009-10-08 ]. www. bioimagene, corn/ pdfs/AboutHer2Testing, pdf.
  • 7Yaziji H, Taylor CR. Begin at the beginning, with the tissue! The key message underlying the ASCO/CAP Task-force Guideline Recommendations for HER2 testing. Appl Immunohistochem Mol Morphol, 2007,15(3) :239-241.
  • 8Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med, 2009,133 ( 5 ) : 775- 780.
  • 9Bang Y J, Chung HC, Xu JM, et al. Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 positivity in the global screening programme of the ToGA trial. 45th ASCO Annual Meeting,Orlando, Florida,U S A, 29 May-2 June 2009. Alexandria:J Clin Oncol,2009.
  • 10Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med,2005, 353 (16) :1659-1672.

共引文献244

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部